



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Yuen, L;Revell, PA;Rosenberg, G;Wagner, J;Littlejohn, M;Bayliss, J;Jackson, K;Tan, SK;Gaggar, A;Kitrinos, K;Subramanian, M;Gane, E;Chan, HLY;Li, X;Bowden, S;Locarnini, S;Thompson, A

Title:

HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B

Date:

2020-10-01

Citation:

Yuen, L., Revill, P. A., Rosenberg, G., Wagner, J., Littlejohn, M., Bayliss, J., Jackson, K., Tan, S. K., Gaggar, A., Kitrinos, K., Subramanian, M., Gane, E., Chan, H. L. Y., Li, X., Bowden, S., Locarnini, S. & Thompson, A. (2020). HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B. *Journal of Viral Hepatitis*, 27 (10), pp.1061-1070. <https://doi.org/10.1111/jvh.13318>.

Persistent Link:

<https://hdl.handle.net/11343/275917>

1

2 DR. LILLY KA WAI YUEN (Orcid ID : 0000-0003-2934-0167)

3 DR. HENRY LY CHAN (Orcid ID : 0000-0002-7790-1611)

4

5

6 Article type : Original Paper

7

8

9 **Original Article**10 **TITLE:**HBV variants are common in the “immune-tolerant” phase of chronic hepatitis B11 **Running Title:**HBV variants in immune-tolerant phase

12 \*Lilly Yuen<sup>1\*</sup>, \*Peter A Revill<sup>1,7\*</sup>, \*Gillian Rosenberg<sup>2\*</sup>, Josef Wagner<sup>1</sup>, Margaret Littlejohn<sup>1</sup>, Julianne Bayliss<sup>1</sup>,  
13 Kathy Jackson<sup>1</sup>, Susanna K. Tan<sup>3</sup>, Anuj Gaggar<sup>3</sup>, Kathryn Kitrinis<sup>3</sup>, Mani Subramanian<sup>3</sup>, Ed Gane<sup>4</sup>, Henry LY  
14 Chan<sup>5</sup>, Xin Li<sup>1</sup>, Scott Bowden<sup>1</sup>, Stephen Locarnini<sup>1</sup>, Alexander Thompson<sup>6</sup>

15 \*These authors contributed equally to this study.

16 1. Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty  
17 Institute for Infection and Immunity, Victoria, 3000, Australia

18 2. National Cancer Research Institute, London, England

19 3. Gilead Sciences, Inc., Foster City, CA USA

20 4. New Zealand Transplant Unit, Auckland, New Zealand

21 5. Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, Hong  
22 Kong

23 6. St Vincent's Hospital, Melbourne, Australia

24 7. Department of Microbiology and Immunology, University of Melbourne, Parkville, 3000, Victoria,  
25 Australia.

26 Corresponding author: Dr. Lilly Yuen. [lilly.yuen@vidrl.org.au](mailto:lilly.yuen@vidrl.org.au)

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/jvh.13318](https://doi.org/10.1111/jvh.13318)

This article is protected by copyright. All rights reserved

27 **Conflict of Interest:**

- 28 • Peter Revill has received research funding from Gilead Sciences.
- 29 • Susanna Tan is an employees of Gilead Sciences
- 30 • Anuj Gaggar, Kathryn Kitrino and Mani Subramanian are employees and stockholders of Gilead Sciences
- 31 • Ed Gane is a member of the Scientific Advisory Board and Speakers Bureau for Gilead Sciences and on
- 32 Scientific Advisory Board for Janssen, VIR, Dicerna and Roche.
- 33 • Henry Chan is an advisor and speaker for Gilead Science
- 34 • Alexander Thompson is on the advisory board for Gilead Sciences, research grant from Gilead Sciences,
- 35 speaker fee for educational activity from Gilead Sciences
- 36 • All remaining co-authors do not have no conflict of interest

37 **Fundings:**

38 The study was funded in part by Gilead Sciences

39 **Ethics:**

40 All subjects in the study have signed an informed consent form prior to screening and in accordance with

41 local regulatory and ethics committee requirements. Experimental protocol in these trials was approved by

42 Gilead Sciences and all local regulatory agencies. The Clinical Trials Gov Identifier for Gilead trial GS-US-203-

43 0101 was NCT0050750.

Manuscript  
Author

44 **ABSTRACT**

45 Nucleos(t)ide analogues (NUC) treatment prevents progression of liver fibrosis in subjects with chronic  
46 hepatitis B (CHB). However, risk for hepatocellular carcinoma (HCC) persists despite viral suppression.  
47 Specific HBV variants have been associated with adverse outcomes, including HCC, however the frequency of  
48 these variants during the seemingly benign immunotolerant (IT) phase is unknown. Next generation  
49 sequencing and detailed virological characterization on a cohort of treatment-naïve IT subjects was  
50 performed to determine the frequency of clinically relevant viral variants. Samples from 97 subjects  
51 (genotype B/C 55%/45%, median HBV-DNA 8.5 log<sub>10</sub> IU/mL, median HBsAg 4.8 log<sub>10</sub>IU/mL, median HBeAg  
52 3.6 log<sub>10</sub> PEIU/mL) were analysed. Despite subjects being in the IT phase, clinically relevant HBV variants  
53 were common at baseline, particularly in the basal core promoter (BCP, overlaps the hepatitis B X (HBx)  
54 gene), precore, and PreS regions. BCP/HBx variants were independently associated with lower baseline  
55 HBeAg, HBsAg and HBV-DNA titres. Precore variants were independently associated with higher baseline  
56 ALT. Increased viral diversity was associated with increased age and lower HBV DNA, HBsAg and HBeAg  
57 levels. Low level (<5%) drug resistance associated amino acid substitutions in the HBV reverse transcriptase  
58 were detected in 9 (9%) subjects at pre-treatment but were not associated with reduced antiviral activity.  
59 Future studies should evaluate whether detection of HBV variant during IT CHB is predictive of progression  
60 to immune clearance and poor prognosis, and whether early initiation of antiviral therapy during IT CHB to  
61 prevent the selection of HBV variants is clinically beneficial.

62 **KEYWORDS:** hepatitis B virus; chronic hepatitis B; immune tolerance; HBV variants; viral diversity

63 **INTRODUCTION**

64 Persistence of hepatitis B virus (HBV) infection is most common in individuals who are exposed as neonates  
65 or young children.(1)The earliest phase of chronic hepatitis B (CHB)infection, termed the immunotolerant (IT)  
66 or the “HBeAg-positive chronic HBV infection” phase of disease, in these subjects is characterized by the  
67 presence of serum HBeAg, very high levels of serum HBV DNA and persistently normal serum ALT levels.The  
68 IT phase has traditionally been thought to represent a benign phase of disease as necroinflammation is mild  
69 and fibrosis progression is unusual.(2)

70 While current guidelines do not recommend initiation of antiviral therapy for IT subjects(3-5),there is  
71 increasing scientific rationale to consider treating these subjects.Sustained viral suppression from a young  
72 age may be associated with reduced hepatocellular carcinoma(HCC) risk.(6)IT subjects have recently been  
73 reported to have a high level of HBV DNA integration and clonal hepatocyte expansions similar to subjects in

74 the HBeAg positive immune clearance phase of CHB infection, suggesting that hepatocarcinogenesis may  
75 already be underway in this early phase of the infection.(7)Recent data also suggest that HBV specific T cell  
76 function is intact in childhood rather than being in a state of immune tolerance, consistent with an early  
77 initiation of an anti-HBV immune response.(8)Few studies evaluating for viral variants using next-generation  
78 sequencing (NGS) technology have been performed in CHB subjects, particularly in IT subjects. This is  
79 important because the selection of HBV variants, including HBeAg-defective variants, such as those with  
80 mutations in the basal core promoter (BCP, A1762T/G1764A) which overlaps the gene of the hepatitis B x  
81 protein(HBx) and/or in the precore (PC, G1896A) of the viral genome may contribute to disease progression  
82 including HCC.(9, 10)The frequency of HBV variants with these mutations or other mutations known to be  
83 associated with adverse disease outcomes, referred to as clinically relevant HBV variants, in the IT phase of  
84 chronic HBV infection is unknown. Identification of these variants and early initiation of antiviral therapy to  
85 prevent their selection may contribute to a reduction in progressive liver disease and HCC risk.

86 Study GS-US-203-0101 was a randomized, double blind study that evaluated the efficacy of antiviral therapy  
87 in IT subjects.(11)HBeAg positive, treatment-naïve individuals with high HBV DNA and normal ALT received  
88 either oral tenofovir disoproxil fumarate (TDF, 300 mg) and placebo (n=64) or a combination of TDF (300 mg)  
89 and emtricitabine (FTC, 200 mg, n=62) for 192 weeks. The primary end point of study was to determine the  
90 proportion of subjects who achieved viral suppression to <69 IU/mL at week 192. Study showed the  
91 treatment was safe and efficacious, and TDF/FTC provided better viral suppression than TDF alone(11), with  
92 55% and 76% of subjects who received TDF and TDF/FTC respectively achieved HBV DNA levels of <69 IU/mL  
93 at end of treatment. Among subjects with on-going low level viraemia, no confirmed TDF resistance  
94 was identified by Sanger sequencing. However, the rate of HBeAg loss was low (5%) and no subjects achieved  
95 HBsAg seroclearance, which was considerably lower compared to observations in IC subjects.(12)No HCC was  
96 observed, although the study was not designed to evaluate HCC as an outcome.

97 To date there have been few detailed studies profiling HBV virology among IT subjects. The aim of the  
98 current study was to perform a detailed virological investigation of baseline and on-treatment samples  
99 from subjects enrolled in Study GS-US-203-0101. We have previously shown that the detection by NGS of HBV  
100 variants with BCP( A1762T/G1764A) and/or PC (G1896A) mutations at baseline was associated with reduced  
101 likelihood of HBsAg loss, even when present in serum at levels as low as 1% of the viral quasispecies  
102 pool(14). We hypothesized that these and other clinically relevant HBV variants that are associated with  
103 disease progression and HCC risk may begin to emerge during the IT phase. Whole HBV genome  
104 sequencing by NGS was performed to identify the presence and frequency of HBV variants with these genetic  
105 changes, which were tested for association with baseline and on-treatment levels of serum HBeAg, HBsAg  
106 and HBV DNA.

## 107 **MATERIALS AND METHODS**

### 108 **Subjects**

109 The inclusion criteria for GS-US-203-101 were: age 18-69yrs., serum HBV DNA level  $>1.7 \times 10^7$  IU/mL, serum  
110 ALT  $\leq$ upper limit of normal (ULN) (men:43 U/L, women:34 U/L), positive serum HBeAg and HBsAg, and  
111 creatinine clearance  $\geq$ 70 mL/min. Subjects with decompensated liver disease, history of HCC, and  
112 co-infection with hepatitis C virus, hepatitis D virus, or human immunodeficiency virus were excluded.(11)A  
113 total of 126 subjects received treatment in GS-US-203-0101, 64 received TDF and 62 received TDF/FTC. This  
114 study was restricted to subjects infected with HBV genotypes B and C (n = 114, 90% of the cohort).

### 115 **Viral load and serological characterisation**

116 HBV viral load and HBsAg quantification were determined previously(11)using the Roche COBAS TaqMan  
117 (Roche Diagnostics, Mannheim, Germany) and Abbott Architect (Abbott Laboratories, Abbott Park, IL)  
118 assays, respectively.The lower limit of quantification for HBV DNA was 29 IU/mLand HBsAg was 0.05  
119 IU/mL.HBeAg levels were determined using the Roche Elecsys HBeAg assay (Roche Diagnostics, Basel,  
120 Switzerland) at the Victorian Infectious Diseases Reference Laboratory (VIDRL) as previously  
121 described.(13)The upper limit of quantification was $>6000$  PEIU/mLand the lower limit was 0.3 PEIU/mL.(13)

### 122 **Next Generationsequencing (NGS)**

123 Whole HBV genome amplification was performed with HBV DNA extracted from 200  $\mu$ l serum using the  
124 QIAamp DNA Minikit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. A genome  
125 length PCR product and an overlapping PCR product covering the primer binding region were generated  
126 usingthe Hi-Fidelity FastStart DNA polymerase (Roche Diagnostics, Basel, Switzerland). PCR products  
127 generated for Sanger sequencing were pooled in a 1:1 molar ratio. Library preparation was performed using  
128 the Nextera XT kit (Illumina, San Diego, CA, USA) and NGS was donewiththe MiSeq platform (Illumina)  
129 according to manufacturer's protocolat Micromon Genomics (Melbourne, Australia).Analysis of NGS data  
130 was performed using the in-house HBV-QuasiMiner software package, as previously described(14) with  
131 minor modifications. Briefly, the package was composed of a number of modules:raw data processing,  
132 quality assurance testing, HBV genotype determination, significant single/multiple nucleotide  
133 variant(SNV/MNV) calling, and auto-deduction of nucleotide to amino acid changes of the respective HBV  
134 genes.The threshold for detection of SNV/MNVusing this approach was established at 1%, compared to  
135 Sanger sequencing (limit of detection  $>20\%$ ).NGS was successfully performed on 97 baseline and 27 on-  
136 treatment (last sample with sufficient viral load for amplification) samples. Sanger sequencing was  
137 performed for validation purposes and mutation analysis across the whole genome was carried out against  
138 genotype specific consensus sequences as described previously.(15-17)

139 **Clinically relevant HBV variants**

140 Each HBV infected subject harbours a unique collection of HBV variants some of which may be associated with  
141 clinically important outcomes. The clinically relevant HBV variants analysed in this study included those with  
142 BCP mutation/deletion at A1762T and G1764A (BCP/HBx variant), PC mutation at G1896A which created a  
143 stop codon at position 28 of the HBe protein sequence (PC variant), PreS1/2 amino acid substitution or  
144 deletion at M1 (PreS variant), S amino acid substitutions within the 'a'-determinant region of the surface  
145 protein sequence (S variant), S amino acid substitution at G145R (vaccine-escape variant), drug resistance  
146 associated amino acid substitutions (RAS) in the RT of HBV polymerase (RAS variants), and the NRE mutation  
147 G1613A (NRE variant).

148 **Viral Diversity Analysis**

149 HBV variants in individual subjects occur at different relative frequencies, and their diversity level can be  
150 assessed by haplotype reconstruction (refer to Supplementary Material and Methods section for detail).  
151 Each reconstructed haplotype was equated to the genome sequence of a specific HBV variant in this study.  
152 Briefly, the NGS short reads were processed using Trimmomatic v0.2.36(18), mapped to a reference genome  
153 using SMALT v0.7.4 (Wellcome Sanger Institute, Cambridge UK), and the HBV genome haplotypes were  
154 reconstructed using CligSNV v1.4.8(19). All haplotypes with a minimum abundance of 1% were used for  
155 analysis.

156 **Phylogenetic Analysis**

157 A maximum likelihood (ML) tree was generated in MEGA7(20) to show the phylogenetic relationships  
158 between all the haplotypes determined from baseline samples with a minimum abundance of 1%.

159 **Statistical Analysis**

160 Statistical analysis between clinical factors and single nucleotide or amino acid variants (SNV or SAV)  
161 detected in baseline and on-treatment samples of subjects were performed with R Statistical Software  
162 (v2.3.1; R Foundation for Statistical Computing, Vienna, Austria). For bivariate analysis, categorical data were  
163 evaluated using the Fisher's exact test, and continuous data using the t-test for parametric data and  
164 Wilcoxon Rank Sum test (or Kruskal-Wallis if more than 2 groups were analysed) for non-parametric data.  
165 Normality of continuous data was assessed using the Shapiro-Wilk normality test. Multiple logistic regression  
166 analysis was performed to determine independent factors associated with treatment response using the R  
167 package MuMIn.(21) All reported P values were 2-sided.

168 Statistical tests on the reconstructed haplotypes were performed using GraphPad Prism version 7.0e  
169 (GraphPad Software, La Jolla California USA, www.graphpad.com) (refer to Supplementary for detail). The t-

170 test was used to evaluate parametric data and Mann Whitney Test for non-parametric data. Normality of  
171 continuous data was tested with both D'Agostino & Pearson and Shapiro-Wilk normality tests. Correlations  
172 between clinical factors and haplotype frequency was assessed by measuring the Pearson correlation  
173 coefficient for parametric data and Spearman correlation coefficient for nonparametric data.

## 174 **Results**

### 175 **i) Subject characteristics**

176 Baseline samples from 53 HBV genotype B and 44 HBV genotype C subjects from the GS-US-203-101 study  
177 were successfully analysed using NGS(97/114 (85%) subjects, Table1). Samples of the remaining 17subjects  
178 could not be amplified or had failed NGS quality control. Thesubjects at baselinewere predominantly young  
179 (median age 31 [IQR 26-40] yrs.), Asian (96%), had high HBV DNA (median viral load 8.4[IQR  
180 8.2-8.6]log<sub>10</sub>IU/mL) and normal ALT (median 26 [IQR 21-31] U/L), consistent with baseline characteristics  
181 described in the overall GS-US-203-101 cohort.(11)

### 182 **ii) Clinically relevant HBV variants were commonat baseline**

183 Whole HBV genome NGS data was generated from baseline samples of 97 subjects, and analysis revealed  
184 presence of clinically revelvanthBV variants was frequent despite the subjects were in the IT phase of CHB  
185 (Table 2), with 87% of subjects had at least one of the described HBV variants that are associated with  
186 adverse disease outcomes. BCP/HBx (n=19, 20%) and NRE (n=72, 74%) variants weremore common in  
187 subjects infected with HBV genotype C than those with genotype B(BCP/HBx 41% vs. 2%, NRE 100% vs. 53%;  
188 p<0.001). Other HBV variants detected include those with genetic variations in the PC, PreS and S regions of  
189 the viral genome. Subjects harbouring HBV variants with BCP/HBx, PC or PreS1/2 M1 immune evasion  
190 associated changes or deletions were older (35yrs vs. 30yrs, p=0.042) and had higher ALT levels (27 U/L vs.  
191 23 U/L, p=0.006). RAS variants(22) were identified at low frequency (<5%) in 9 subjects.

### 192 **iii) BCP/PC variants were associated with HBeAg, HBsAg, HBV DNA and ALT levels at baseline**

193 The associations between the BCP/HBx and PC variants and serum HBsAg, HbeAg, HBV DNA and ALT levelsof  
194 subjects at baselinewere assessed. The frequency of BCP/HBx variants when present at>1% was negatively  
195 correlated with HBsAg (r=-0.503; p=0.028), HbeAg (r=-0.651; p=0.003), and HBV DNA levels (r=-0.446;  
196 p=0.056). Furthermore, subjects with BCP/HBx variants present at>20% of the quasispecies pool (n=9,  
197 detectable by Sanger sequencing) had significantly lower HbeAg (p=0.033), HBsAg (p=0.001) and HBV DNA  
198 (p=0.016) levelsthan those with only wildtype (WT) variants (n=75) (Figure 1). Notably, subjects with PC  
199 variants even at low levels (>1%, n=11) had significantly higher ALT levels than those infected with WT

200 variants (n=43)(p=0.015).However, since all IT subjects by definition have low ALT levels, the biological  
201 relevance of these small yet statically significant differences is unclear.

#### 202 **iv) An increase in viral diversity may indicate transition towards immune clearance phase**

203 The median number of haplotypes determined from the IT cohort at baseline was 3 [IQR: 2 to 5].  
204 The relationship between viral diversity level in subjects and clinical factors at baseline were  
205 assessed. Haplotype reconstruction showed that the level of viral diversity, expressed as number of  
206 haplotypes per sample, correlated with baseline serum ALT level (r=0.314 and p=0.002)(Figure 2). In addition,  
207 the level of viral diversity correlated with age of subjects (r = 0.367 and p <0.001), negatively correlated  
208 albeit weakly with HBV DNA (r = -0.264 and p = 0.012), HbeAg (r = -0.254 and p <0.001) and HBsAg (r = -0.418  
209 and p <0.001) levels at baseline. Viral diversity level also differed significantly by HBV genotype (p  
210 <0.001, Figure 3), being higher in subjects infected with HBV genotype C (median = 4; IQR 2 to 6) than HBV  
211 genotype B (median = 2; IQR 2 to 3). No subjects were infected with mixed HBV genotypes by phylogenetic  
212 analysis, and all haplotypes clustered correctly in the maximum likelihood tree by the expected HBV  
213 genotype (data not shown). Interestingly, the majority of the BCP/HBx variant haplotypes were determined  
214 from HBV genotype C subjects (data not shown).

#### 215 **v) Baseline HBV variants were not associated with treatment response**

216 Finally, we assessed whether baseline HBV variants can inform response to antiviral therapy in IT subjects. Of  
217 77 subjects with a complete set of serological data available at week 192, 66% achieved viral suppression of  
218 serum HBV DNA to <29 IU/mL (59% among TDF treated and 76% among FTC/TDF treated), 15% had >1  
219 log<sub>10</sub> IU/mL decline in serum HBsAg, and 29% had >1 log<sub>10</sub> PEIU/mL decline in serum HbeAg at end of  
220 treatment. Female subjects in this cohort were more likely to achieve viral suppression to <29 IU/mL at  
221 week 192 than male subjects (Table 3), consistent with the parent study.(11)

222 Baseline clinically relevant HBV variants were not associated with reductions in HBV viral load or HBsAg, but  
223 presence of the BCP/HBx variant (p=0.006), and higher viral diversity (haplotype count, p=0.005) at baseline  
224 was independently associated with >1 log<sub>10</sub> decline in serum HbeAg at week 192 by univariate analysis  
225 (Table 3). The dynamics of HBsAg and HbeAg change were also explored, with both markers exhibiting a  
226 biphasic decline over 192 weeks of treatment (Supplementary Figure 1).

#### 227 **vi) Persistent viraemia was not associated with selection of drug resistance associated substitutions**

228 RAS variants were detected at low frequency in 9(9%) subjects at baseline (Tables 2 and 4). The lamivudine  
229 (LMV) resistance associated rtM204I substitution(22) was detected in 5 of the 9 subjects, the LMV and adefovir  
230 (ADV) resistance associated rtA181S/T substitution(22) was detected in 3 subjects, and a subject had viral  
231 variants with both rtM204I and rtA181T substitutions. All RAS were detected at levels below 5% of the HBV

232 quasispecies pool, well below the 20% Sanger sequencing detection threshold, and were not associated with  
233 viral suppression in response to TDF treatment.

234 The quadruple mutation (rtS106C, rtH126Y, rtD134E and rtL269I, collectively referred to as the CYEI  
235 mutation) that may be associated with reduced sensitivity to TDF(23), recently identified in two patients(23),  
236 was not detected in the samples of any of the subjects.

237 No subjects with RAS variants at baseline experienced virological breakthrough nor HBeAg loss by week 192.  
238 Moreover, on-treatment samples from 4 subjects were successfully analysed by NGS, and the RAS variants  
239 were no longer detected (Table 4).

## 240 DISCUSSION

241 This is the first detailed study of HBV sequence variability in the setting of IT CHB. The standard clinical  
242 definition of ITCHB includes HbeAg positivity, high HBV DNA, normal ALT and minimal hepatic  
243 necroinflammation(1), with current clinical guidelines not recommending treatment for this phase.(3-5) This  
244 study has identified prevalent clinically relevant HBV variants among a cohort of subjects at baseline in the  
245 IT phase of CHB. Increase HBV diversity was associated with clinical factors suggestive of transition to IC  
246 phase disease, despite persistently normal ALT. HBV variants previously associated with disease progression  
247 (cirrhosis and HCC) were common using NGS and were detected in 87% of the cohort.

248 Of note, the BCP/HBx mutations/deletions located at nucleotide positions 1762 and 1764 of the HBV  
249 genome (BCP/HBx variant) was detected at baseline by NGS in 20% of the IT subjects. Presence of the  
250 BCP/HBx variant was associated with lower baseline levels of HbeAg, HBsAg and HBV DNA. This association  
251 was independent of gender and HBV genotype. Similarly, mutations or amino acid substitutions in the PC,  
252 core Pre-S and NRE regions of HBV genomes were detected in IT subjects. Analysis of viral diversity by  
253 haplotype reconstruction of NGS data confirmed that increased diversity was associated with clinical  
254 features suggestive of progression towards the immune clearance phase of CHB, including lower HBV DNA  
255 levels, HBsAg and HbeAg levels. Sequence diversity also varied by HBV genotype, with higher levels of  
256 sequence diversity in HBV genotype C than genotype B in IT subjects. The data suggest that the viral  
257 population is diverse during the IT phase of CHB, which we speculate reflects host-virus interaction but this  
258 requires further experimental confirmation. Future studies should evaluate the association between  
259 selection of HBV variants during the IT phase and markers of anti-HBV immunity.

260 The presence of clinically relevant HBV variants has been associated with clinical outcomes.  
261 BCP/HBx variants have been associated with disease progression, cirrhosis, and HCC.(10, 24) Variants with  
262 mutations/deletions in the PC and Pre-S regions of viral genomes have also been associated with increased  
263 HCC risk(10, 25). Long-term viral suppression with NUC therapy reduces HCC risk when treating subjects with

264 cirrhosis (26). Given the excellent long-term efficacy, resistance and safety profiles, the European  
265 guidelinessuggest that treatment be considered in IT subjects if they are older than 30 years, regardless of  
266 the severity of liver histological lesions(27)). Detection of HBV variants associated with HCC risk in IT subjects  
267 with a mean age of 32 yrs in our study supports this approach. Prospective studies are required to evaluate  
268 whether commencing immunotolerant subjects on NUC therapy before the selection of HBV variants will be  
269 associated with a risk reduction for progression to HCC.

270 Another important clinical question is whether commencing treatment in IT subjects with very high viral  
271 loads would be associated with an increase in the risk of antiviral resistance. Despite subjects in this study  
272 having very high baseline HBV DNA levels, variants with resistance to tenofovir were not identified, although  
273 very low levels of variants with resistance to other NUC's were detected.

274 In summary, our data shows that clinically relevant HBV variants associated with increased risk of liver  
275 morbidity and mortality were detected in IT subjects. We surmise that individuals who may be transitioning  
276 to IC phase have an increase in viral haplotype diversity, and suggest that the classification of  
277 "immunotolerant CHB" may need to be revisited to consider the role of detectable viral evolution within the  
278 clinical definition. Further studies of subjects who transition from IT to IC phases are required, as are studies  
279 to evaluate the clinical benefit of early antiviral therapy to prevent the selection of HBV variants and reduce  
280 the risk of HCC.

## 281 REFERENCES

- 282 1 McMahon BJ. Natural history of chronic hepatitis B. *Clin Liver Disease*. 2010; 14(3):381-96.
- 283 2 Tseng TC, Kao JH. Treating Immune-tolerant Hepatitis B. *J Viral Hepat*. 2015; 22(2):77-84.
- 284 3 EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol*. 2012;  
285 57(1):167-85.
- 286 4 Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology*. 2009; 50(3):661-2.
- 287 5 Liaw Y-F, Kao J-H, Piratvisuth T, *et al*. Asian-Pacific consensus statement on the management of  
288 chronic hepatitis B: a 2012 update. *Hepatol Int*. 2012; 6(3):531-61.
- 289 6 Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. *Gut*. 2012;  
290 61(3):333-6.
- 291 7 Mason WS, Gill US, Litwin S, *et al*. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic  
292 Hepatitis B Patients Considered Immune Tolerant. *Gastroenterology*. 2016; 151(5):986-98 e4.
- 293 8 Kennedy PTF, Sandalova E, Jo J, *et al*. Preserved T-cell function in children and young adults with  
294 immune-tolerant chronic hepatitis B. *Gastroenterology*. 2012; 143(3):637-45.

- 295 9 Liao G, Wang Y, Chang J, *et al.* Hepatitis B virus precore protein augments genetic immunizations of  
296 the truncated hepatitis C virus core in BALB/c mice. *Hepatology*. 2008; 47(1):25-34.
- 297 10 Tseng TC, Liu CJ, Yang HC, *et al.* Higher proportion of viral basal core promoter mutant increases the  
298 risk of liver cirrhosis in hepatitis B carriers. *Gut*. 2015; 64(2):292-302.
- 299 11 Chan HL, Chan CK, Hui AJ, *et al.* Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-  
300 Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus  
301 DNA. *Gastroenterology*. 2014; 146(5):1240-8.
- 302 12 Marcellin P, Gane E, Buti M, *et al.* Regression of cirrhosis during treatment with tenofovir disoproxil  
303 fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet*. 2013; 381(9865):468-75.
- 304 13 Zacher BJ, Moriconi F, Bowden S, *et al.* Multicenter evaluation of the Elecsys hepatitis B surface  
305 antigen quantitative assay. *Clin Vaccine Immunol*. 2011; 18(11):1943-50.
- 306 14 Bayliss J, Yuen L, Rosenberg G, *et al.* Deep sequencing shows that HBV basal core promoter and  
307 precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in  
308 HBeAg-positive chronic hepatitis B. *Gut*. 2017; 66(11):2013-23.
- 309 15 Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of  
310 whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in  
311 immunosuppressed patients. *J Virol*. 1995; 69(9):5437-44.
- 312 16 Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. *Methods*  
313 *Mol Med*. 2004; 95:125-49.
- 314 17 Yuen LK, Ayres A, Littlejohn M, *et al.* SeqHepB: a sequence analysis program and relational database  
315 system for chronic hepatitis B. *Antiviral Res*. 2007; 75(1):64-74.
- 316 18 Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data.  
317 *Bioinformatics*. 2014; 30(15):2114-20.
- 318 19 Knyazev S, Tsyvina V, Melnyk A, *et al.* CliqueSNV: Scalable reconstruction of Intra-host viral populations  
319 from NGS reads. *BioRxiv*. 2018; 264242.
- 320 20 Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for  
321 Bigger Datasets. *Mol Biol Evol*. 2016; 33(7):1870-4.
- 322 21 Barton K. Mu-MIn: Multi-model inference. R Package Version 0.12.2/r18. 2009; [http://R-Forge.R-](http://R-Forge.R-project.org/projects/mumin/)  
323 [project.org/projects/mumin/](http://R-Forge.R-project.org/projects/mumin/).
- 324 22 Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. *Gastroenterology*. 2009;  
325 137(5):1593-608 e1-2.

- 326 23 Park ES, Lee AR, Kim DH, *et al.* Identification of a quadruple mutation that confers tenofovir resistance  
327 in chronic hepatitis B patients. *J Hepatol.* 2019; 70(6):1093-102.
- 328 24 Tong S, Kim KH, Chante C, Wands J, Li J. Hepatitis B Virus e Antigen Variants. *Int J Med Sci.* 2005;  
329 2(1):2-7.
- 330 25 Liao Y, Hu X, Chen J, *et al.* Precore mutation of hepatitis B virus may contribute to hepatocellular  
331 carcinoma risk: evidence from an updated meta-analysis. *PLoS One.* 2012; 7(6):e38394.
- 332 26 Papatheodoridis GV, Idilman R, Dalekos GN, *et al.* The risk of hepatocellular carcinoma decreases after  
333 the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. *Hepatology.* 2017;  
334 66(5):1444-53.
- 335 27 EASL. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J*  
336 *Hepatol.* 2017; 67(2):370-98.
- 337 28 Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to Inhibit Entry of HBV and HDV into  
338 Hepatocytes. *Gastroenterology.* 2014; 147(1):48-64.
- 339 29 Mun HS, Lee SA, Jee Y, *et al.* The prevalence of hepatitis B virus preS deletions occurring naturally in  
340 Korean patients infected chronically with genotype C. *J Med Virol.* 2008; 80(7):1189-94.
- 341 30 Pollicino T, Amadeo G, Restuccia A, *et al.* Impact of hepatitis B virus (HBV) preS/S genomic variability  
342 on HBV surface antigen and HBV DNA serum levels. *Hepatology.* 2012; 56(2):434-43.
- 343 31 Blackberg J, Kidd-Ljunggren K. Mutations within the hepatitis B virus genome among chronic hepatitis  
344 B patients with hepatocellular carcinoma. *J Med Virol.* 2003; 71(1):18-23.
- 345 32 Zhang D, Dong P, Zhang K, *et al.* Whole genome HBV deletion profiles and the accumulation of preS  
346 deletion mutant during antiviral treatment. *BMC Microbiol.* 2012; 12:307.
- 347 33 Chotiyaputta W, Lok AS. Hepatitis B virus variants. *Nat Rev Gastro Hepat.* 2009; 6(8):453-62.
- 348 34 Carman WF, Zanetti AR, Karayiannis P, *et al.* Vaccine-induced escape mutant of hepatitis B virus.  
349 *Lancet.* 1990; 336(8711):325-9.
- 350 35 Li MS, Lau TC, Chan SK, *et al.* The G1613A mutation in the HBV genome affects HBeAg expression and  
351 viral replication through altered core promoter activity. *PLoS one.* 2011; 6(7):e21856.
- 352 36 Nie H, Evans AA, London WT, Block TM, Ren XD. Quantitative dynamics of hepatitis B basal core  
353 promoter and precore mutants before and after HBeAg seroconversion. *J Hepatol.* 2012; 56(4):795-  
354 802.

355 37 Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a  
 356 consequence of treatment failure. *Hepatol Int.* 2008; 2(2):147-51.

357 **Table 1:** Comparison between baseline characteristics of subjects who had samples successfully assessed by  
 358 NGS and those of the original study. (11)

	NGS Cohort (N = 97)		Original Study (N = 114)		p-values
Age (yrs), median [IQR]	33	[26-42]	34	[26-40]	0.535
Male, n (%)	45	(46)	54	(47)	0.891
Asian, n (%)	92	(95)	109	(96)	1
TDF monotherapy, n (%)	53	(55)	56	(49)	0.490
ALT (U/m), median [IQR]	25	[20-31]	26	[21-31]	0.679
HBV DNA (log <sub>10</sub> IU/mL), median [IQR]	8.5	[8.2-8.6]	8.4	[8.2-8.6]	0.962
HBsAg (log <sub>10</sub> IU/mL), median [IQR]	4.8	[4.6-5.0]	4.7	[4.6-5.0]	0.571
HbeAg (log <sub>10</sub> PE IU/mL), median [IQR]	3.6	[3.4-3.7]	3.5	[3.4-3.7]	0.872
HBV Genotype, n (%)	B	53 (55)	64	(56)	0.890
	C	44 (45)	50	(44)	0.899

359

360 **Table 2:** Baseline HBV variants with specific mutations or amino acid substitutions in the viral genome that  
 361 have previously been associated with clinical phenotype, present at >1% frequency, that were detected by  
 362 NGS from 97 subjects.

Mutations/Amino Acid Substitutions (+)	Associated phenotype	N (%) (#)	Median frequency [IQR] when detected by NGS
PreS1 M1	Loss of large HBsAg, associated with infectivity(28), disease progression(29) and decreased HBsAg(30)	33 (34%) (B=17; C=16)	2% [1-9] (B: 1% [1-2]) (C: 11% [4-25])
PreS2 M1	Loss of medium HBsAg, associated with viral secretion(28), disease progression(31) and decreased HBsAg(30)	10 (11%) (B=2; C=8)	4% [3-20] (B: 22% [12-32]) (C: 4% [3-13])
PreS deletions (excluding those that involved M1)	Truncated large/medium HBsAg associated with decreased HBsAg(30) and immune escape(32)	5 (5%) (C=5)	20% [6-27] -
HBsAg 'a' determinant (codons 120-150)	Major antigenic region of the protein(33) and variants can lead to vaccine, immune, and diagnostic escape	43 (61%) (B=26; C=17)	2% [1-3] (B: 1% [1-2]) (C: 2% [1-3])
HBsAg G145G/R	Known vaccine escape variant(34)	10 (10%) (C=10)	12% [4-20] -

RT L80, A169, V173, L180, A181*, T184, S202, M204*, N236*, M250	Known drug resistance and compensatory variants(22)	9 (9%) § (B=4; C=5)	1% [1-2] (B: 1% [1-2]) (C:2% [1-2])
NRE G1613A	Associated with an increased risk of HCC in genotype C and alongside the BCP mutation(35), increase viral expression(35) and decreased HBeAg secretion(35)	72 (74%) (B=28; C=44)	4% [1-19] (B: 4% [1-25]) (C:4% [2-17])
BCP (mutations/deletions involving sites A1762 and G1764)	Associated with lower HBeAg expression, higher viral loads, disease progression(33). Suggestive of upcoming HBeAg seroconversion(36).	19 (20%) (B=1; C=18)	28% [4-73] (B: 53%) (C:25% [4-80])
Precore (G1896G/A)	Associated with loss of HBeAg(33). Suggestive of upcoming HBeAg seroconversion(36).	13 (15%) (B=7; C=6)	9% [3-20] (B: 13% [3-29]) (C: 9% [7-18])

363 †RT = reverse transcriptase, NRE = negative regulatory region, BCP = basal core promoter

364 ‡ Number (percentage) of subjects with the mutation/amino acid substitution

365 §10 HBVRT amino acid substitutions are associated with drug resistance(37) and were screened for in this study, but only viral  
366 variants with at least one of the 3 primary resistance substitutions flagged with asterisk are considered a drug resistant variant. The  
367 others are secondary resistance associated substitutions. The RAS profiles of the 9 subjects are shown in Table 4.

Author Manuscript

368 **Table 3:** Association of viral variants with clinically relevant nucleotide/amino acid changes detected by NGS at baseline and associated clinical markers with  
 369 antiviral therapy response at 192 weeks

Baseline characteristics	Viral suppression (†)			HBsAg >1 log <sub>10</sub> decline			HBeAg >1 log <sub>10</sub> decline		
	R (N = 54)‡	NR (N = 27)‡	p-value§	R (N = 12)‡	NR (N = 67)‡	p-value§	R (N = 24)‡	NR (N = 57)‡	p-value§
TDF monotherapy, n (% of N)	26 (48)	19 (70)	0.068	6 (50)	37 (55)	0.763	15 (63)	30 (53)	0.470
Age, median [IQR]	34 [26-45]	32 [27-39]	0.627	30 [23-44]	33 [27-42]	0.461	36 [26-46]	32 [27-41]	0.612
Female Gender, n (% of N)	32 (59)	9 (33)	<b>0.035</b>	4 (33)	36 (54)	0.224	11 (46)	30 (53)	0.632
ALT, median [IQR]	24 [21-30]	28 [23-35]	0.218	28 [24-35]	24 [20-31]	0.127	28 [24-35]	24 [20-30]	<b>0.006</b>
HBV DNA, median [IQR]	8.4 [8.2-8.6]	8.5 [8.3-8.8]	0.331	8.6 [8.4-8.6]	8.4 [8.2-8.6]	0.541	8.4 [8.0-8.6]	8.5 [8.3-8.7]	0.102
HBsAg, median [IQR]	4.8 [4.5-5.0]	4.9 [4.8-5.1]	0.070	4.8 [4.6-5.1]	4.8 [4.6-5.0]	0.778	4.5 [4.3-4.8]	4.9 [4.7-5.0]	<b>0.005</b>
HBeAg, median [IQR]	3.6 [3.3-3.7]	3.6 [3.4-3.6]	0.670	3.5 [3.3-3.6]	3.6 [3.4-3.7]	0.244	3.5 [3.3-3.7]	3.6 [3.4-3.7]	0.757
Genotypes C, n (% of N)	31 (57)	12 (44)	0.346	3 (25)	39 (58)	0.057	13 (54)	30 (53)	1.000
BCP/HBx (A1762T, G1764A), n (% of N)	14 (26)	3 (11)	0.155	1 (8)	15 (22)	0.442	10 (42)	7 (12)	<b>0.006</b>
Precore (G1896A), n (% of N)	7 (13)	4 (15)	1.000	2 (17)	9 (13)	0.671	4 (17)	7 (12)	0.724
PreS1/2 (M1, deletion), n (% of N) ¶	19 (35)	10 (37)	1.000	5 (42)	22 (33)	0.742	9 (38)	20 (35)	1.000
HBsAg ('a' determinant), n (% of N)	19 (35)	14 (52)	0.161	4 (33)	27 (40)	0.756	13 (54)	20 (35)	0.140
HBsAg (G145R), n (% of N)	7 (13)	2 (7)	0.710	1 (1)	8 (12)	0.674	6 (25)	3 (5)	<b>0.017</b>
Drug-resistant changes, n (% of N)	12 (22)	8 (30)	0.586	4 (33)	15 (22)	0.469	5 (21)	15 (26)	0.779
NRE (G1613A), n (% of N)	41 (76)	24 (89)	0.240	7 (58)	56 (84)	0.060	18 (75)	47 (82)	0.543
Haplotype Count, median [IQR]	3 [2-5]	2 [1-4]	0.089	3 [2-4]	3 [2-5]	0.989	4 [2-8]	2 [2-4]	<b>0.005</b>

370 †Number of subjects who achieved viral suppression of serum HBV DNA to <29 IU/mL

371 ‡ R = responders; NR = non-responders

372 § p-values in bold and italic font are statistically significant

373 ¶ PreS: include the 3 amino acid changes/deletions categories listed in Table 2

374 **Table 4:** Summary of drug-resistance associated amino acid substitutions (RAS) identified in the reverse transcriptase domain of HBV polymerase  
 375 and overlapping HBsAg, at baseline in 9/97 subjects by NGS.

Subject† (Genotype)	Treatment	RAS Profile at baseline (%)	Overlapping HBsAg changes at baseline	HBeAg at Baseline (log <sub>10</sub> PEIU/mL)	VL at Baseline (log <sub>10</sub> IU/mL)	VL at week 192 (IU/mL)	VL first week <29 IU/ml	ALT at Baseline (U/L)	HBeAg >1 log <sub>10</sub> decline at week 192	HBsAg >1 log <sub>10</sub> decline at week 192
1 (C)	TDF	A181T (1.1) + M204I (1.9) + M250I (1.1)	W172*+W196*	3.60	8.36	<29	96	31	N	N
2 (C)	TDF	M204I (1.3) + M250I (1.2)	W196*	3.25	7.65	<29	48	21	Y	Y
3 (B)	TDF	A181T (1.4) + M250I (3.6)	W172*	3.66	8.71	44	160	15	N	N
4 (B)	TDF + FTC	M204I (1.5) + M250I (3.6)	W196L	3.20	8.61	<29	96	24	N	N
5 (C)	TDF	A181S (1.7)	W172C	3.35	9.02	90	72	29	N	N
6 (B)	TDF	M204I (1.6) + M250I (2.7)	W196L	3.26	8.45	early EOT	-	29	N	N
7 (B)	TDF	M204I (1.2) + M250I (1.6)	W196L	3.29	8.52	32	160	17	N	N
8 (C)	TDF + FTC	A181S/T (3.6/2.7)	W172C/*	1.33	7.87	<29	48	26	N	N
9 (C)	TDF	M204I (2.0)	W196*	1.97	7.42	<29	48	23	Y	N

376 † Second samples of Subjects 3 (week 24), 5 (week 24), 6 (week 24), and 7 (week 8) were successfully analysed by NGS, and no RAS variants were detected.

377


378 **FIGURE LEGENDS**

379 **Figure 1:** Baseline levels of HBsAg, HBeAg, HBV DNA and ALT determined from subjects infected with  
380 immune/drug susceptible viral variants (WT), and those with BCP/HBx (BCP), PC and BCP+PC variants present  
381 at different frequencies (>20%, >10% and >1%). Subject groups with significantly different serological  
382 biomarker levels are marked with a bar above the boxplots.


383 **Figure 2:**Correlation relationships between viral diversity level (number of haplotypes), serological markers,  
384 and age of subjects at baseline. Number of haplotypes versus: (a) ALT level, (b) HBV DNA level, (c) HBsAg  
385 level, (d) HBeAg level, and (e) subject age.

386 **Figure 3:** Distribution of haplotype frequency determined from subjects with HBV genotype B and C  
387 infections.


Author Manuscript



jvh\_13318\_f1.tif



jvh\_13318\_f2.tif



jvh\_13318\_f3.tif